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Summary The applicability and limitations of a photodynamic threshold model, used to describe
quantitatively the in vivo response of tissues to photodynamic therapy, are currently being investigated in a
variety of normal and malignant tumour tissues. The model states that tissue necrosis occurs when the number
of photons absorbed by the photosensitiser per unit tissue volume exceeds a threshold. New Zealand White
rabbits were sensitised with porphyrin-based photosensitisers. Normal brain or intracranially implanted VX2
tumours were illuminated via an optical fibre placed into the tissue at craniotomy. The light fluence distribution
in the tissue was measured by multiple interstitial optical fibre detectors. The tissue concentration of the
photosensitiser was determined post mortem by absorption spectroscopy. The derived photodynamic threshold
values for normal brain are significantly lower than for VX2 tumour for all photosensitisers examined.
Neuronal damage is evident beyond the zone offrank necrosis. For Photofrin the threshold decreases with time
delay between photosensitiser administration and light treatment. No significant difference in threshold is found
between Photofrin and haematoporphyrin derivative. The threshold in normal brain (grey matter) is lowest for
sensitisation by 56-aminolaevulinic acid. The results confirm the very high sensitivity of normal brain to
porphyrin photodynamic therapy and show the importance of in situ light fluence monitoring during
photodynamic irradiation.
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Photodynamic therapy (PDT), a treatment using a light-
activated drug (photosensitiser), is an investigational therapy
for several forms of cancer (Marcus and Dugan, 1992). The
photosensitiser, selectively accumulated or retained in
neoplastic tissue, produces cytotoxic substances upon
activation with light, resulting typically in gross haemor-
rhagic tissue necrosis.
Intraoperative local treatment of primary or recurrent
malignant brain tumours by PDT is currently being
investigated, and several phase I/II clinical trials have been
reported with evidence of increased survival time (Kostron et
al., 1990; Muller and Wilson, 1991; Kaye and Hill, 1993).
Depending on the clinical situation, tumour mass, location
and previous local treatments, PDT is given with or without
prior surgical resection of the tumour and either as a stand-
alone treatment (Muller and Wilson, 1990; Powers et al.,
1991) or in combination with radiation or chemotherapy
(Kaye, 1989; Noske et al., 1991). Both intracavitary (Muller
and Wilson, 1993) and interstitial techniques (Muller and
Wilson, 1991; Powers et al., 1991) have been used. A critical
issue with either technique is the degree of tumour selectivity
that can be achieved. The uptake of photosensitiser into
tumour may be consistently greater than in normal brain,
owing to the intact blood-brain barrier (BBB) of the latter.
However, low intrinsic sensitivity of normal brain compared
with malignant tissue is also desirable in order to minimise
damage to brain adjacent to tumour (BAT), which is within
the light treatment field. Haemorrhagic necrosis of malignant
and normal brain tissue in patients following PDT has been
reported (Muller and Wilson, 1990; Kaye and Hill, 1993).
In this preclinical study a photodynamic threshold model
has been used to describe the dependence of the extent of
PDT-induced tissue necrosis on light and photosensitiser
doses. The model (Patterson et al., 1990) was derived from
the observation of a sharp boundary that usually occurs
between PDT-induced tissue necrosis and undamaged
adjacent tissue (Berenbaum et al., 1982; Potter, 1989). The
model states that, for a given tissue and photosensitiser
combination, necrosis will occur if the number of photons
absorbed by the photosensitiser per unit tissue volume
exceeds a threshold value (1). Thus, a low intrinsic PDT
sensitivity corresponds to a high T-value, and vice versa. The
photodynamic threshold is calculated from measured values
of the depth (or radius) of coagulative tissue necrosis (re), the
light fluence [H(r,)] at the necrosis boundary, and the
photosensitiser concentration in the tissue (C). The model
has been tested in various in vivo animal tumour models and
normal tissues (Farrell et al., 1991, 1992a; Q Chen, private
communication) and has been shown to predict accurately
the radius or depth of necrosis.
Only a limited number of quantitative studies describing
intracranial tissue response to PDT in preclinical animal
models have been published. Evidence to date (Dereski et al.,
1991; Chen et al., 1992a,b; Lilge et al., 1993a; Ying et al.,
1994) suggests that the photodynamic threshold model holds
also for intracranial tissues. Kaye and Morstyn (1987), using
haematoporphyrin derivative (HpD) at 20 mg per kg body
weight (bw) and 200 J cm-2 of surface light dose, and
Sandeman et al. (1987), using trisulphonated aluminium
chlorophthalocyanine at 0.5 mg per kg bw and 700 J cm-2,
observed selective tumour kill in intracranial murine tumour
models, while normal brain tissue showed no, or very limited
necrosis under these treatment conditions.
Several authors (Cheng et al., 1984; Dereski et al., 1991;
Chen et al., 1992a; Leach et al., 1993; Ying et al., 1994)
have noted a very high sensitivity of normal brain tissue to
PDT using Photofrin as photosensitiser. The first histologi-
cally observable changes in normal brain are in structures
associated with the BBB, such as endothelial cell damage
(Berenbaum et al., 1986) and astrocytic swelling (Yoshida et
al., 1992a). Neuronal injury (Yoshida et al., 1992b) was
observed only at longer time delays post PDT. Lindsay et al.
(1991) observed photodynamic resistance for intra-
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tumour grown subcutaneously appeared sensitive using
tetra-m-(hydroxyphenyl) porphyrin (m-THPP) as photosensi-
tiser.
These various data suggest differences in the threshold
values of porphyrin-based photosensitisers in the photody-
namic response of normal brain tissue, and in particular a
higher threshold for HpD compared with Photofrin.
[Photofrin (Quadralogic Technologies, Vancouver, BC,
Canada) or porfimer sodium, is a commercial version of
HpD that is enriched in components believed to have
enhanced tumour localisation and high PDT activity.]
The aim of the present study was to determine and
compare the PDT thresholds for intracranial PDT of normal
brain and an implanted tumour model in the rabbit brain for
three porphyrin-based photosensitisers, namely Photofrin,
HpD and 56-aminolaevulinic acid (5-ALA), a precursor of
the haem synthesis pathway that leads to the in situ
production of the photosensitiser protoporphyrin IX (PpIX)
(Kennedy and Pottier, 1992). Additionally, the feasibility of
using an optical fibre detector array for interstitial fluence-
rate monitoring and determination of tissue optical properties
in vivo is demonstrated.
Materials and methods
Animal model and preparation
Experiments were performed in male New Zealand White
(NZW) rabbits, 2.5-3.8 kg bw. The animals were rando-
mised for PDT treatment according to (i) implanted VX2
tumour or normal brain; (ii) photosensitiser type; and (iii)
time delay between photosensitiser injection and light
irradiation. Table I lists the five study groups. Three animals
received light treatment without prior photosensitiser
injection in order to investigate possible tissue effects from
heating caused by light absorption or from photoactivation
of endogenous porphyrins. In a further rabbit interstitial
temperature measurements in normal brain were made to
check the possibility of temperature changes during light
irradiation.
The VX2 tumour is a high-grade carcinoma derived from
a virus-induced papilloma in a domestic rabbit in 1937
(Carson et al., 1982). For these experiments the cell line was
propagated i.m. in the flank of NZW rabbits with monthly
passages. The experiments extended over a 15 month period.
For tumour implant into the brain, a cell suspension was
prepared from freshly excised VX2 tumour in sterile
phosphate-buffered saline (PBS). The number of VX2 cells
(approximately 105) required to grow an intracerebral tumour
of approximately 10-14 mm diameter in 14 days was
determined in preliminary experiments. For tumour induc-
tion the animals were anaesthetised with i.m. injection of
1 mg per kg bw acepromazine (Atravet; Ayerot, Montreal,
Quebec, Canada) followed by 5 mg per kg bw xylazine
(Rompun; Haver-Lockhart, Etobicoke, Ontario, Canada),
and 50 mg per kg bw ketamine (Ketalean; MTC Pharma-
ceuticals, London, Ontario, Canada). For local anaesthesia
1 ml of 2% xylocaine was injected into the scalp. The skull
was exposed and a 3 mm burr hole drilled in the left parietal
Intracranial photodynamic therapy
L Lilge et al 0
333
bone, 5 mm posterior to the coronal suture and 5 mm lateral
to the sagittal suture. A 25-50 jil cell suspension containing
approximately 105 cells was injected through the burr hole
into the brain to a depth of 5-6 mm using a 25 G needle
(Brem et al., 1990). After injection the burr hole was closed
with bonewax and the scalp incision sutured. After 14 days,
before PDT, on inspection of the brain cortex at craniotomy,
tumour was sometimes visible at the injection site and in
some cases also attached to the dura. This 'leakage' of
tumour cells, which occurred mainly in the first few animals
in which the injection technique had not been perfected, did
not cause any obvious inflammatory response and the bulk of
the tumour mass remained well defined. The problem could
be eliminated by implantation of the cells in agarose gel as
reported by Kaye et al. (1985).
PDT treatment
Photofrin was injected i.v., 10 mg per kg bw at 4-6, 24 or
48 h before light activation. For comparison, two animals
were injected i.v. with HpD (supplied by Queen Elizabeth
Hospital, Woodville, Australia) at 10 mg per kg bw 24 h
before light activation, and three animals were injected i.v.
with 5-ALA as hydrochloride (98% purity) (Sigma Scientific,
St Louis, MO, USA) at 100 mg per kg bw 6 h before light
activation. These injected doses are in the range ofcommonly
used doses in preclinical research (Dereski et al., 1991; Chen
et al., 1992a; Yoshida et al., 1992a). For i.v. injection,
Photofrin and HpD solutions were made up in 5% dextrose
to 10 mg ml-' and 5 mg ml-' respectively. 5-ALA was made
up in PBS to 80 mg ml-I and pH balanced to 7.1 with
sodium hydroxide (0.1 N).
An air cooled argon-ion laser (Ion Laser Technologies,
Salt Lake City, UT, USA) operating in multiline mode
(A=465/488/514 nm) or single-line mode (A= 514 nm) was
used as the light source [630 nm is commonly used for these
photosensitisers, but a shorter wavelength was chosen in
order to confine the treatment to within the tumour volume;
previous work has shown that this does not change the
measured threshold values (Patterson et al., 1990)]. The light
was coupled via a microscope objective lens into a fused silica
optical fibre (numerical aperture 0.25; 320 gm core diameter,
415 gm outer diameter; Polymicro Technologies, Phoenix,
AZ, USA). The numerical aperture was slightly overfilled at
the input face to obtain a reproducible angular distribution
of the light at the cleaved and polished distal end. For
introduction into the cranium the fibre was held flush with
the end of a 21 G biopsy needle. The delivered power was
measured with a thermopile (Scientech, Boulder, CO, USA)
immediately before and after irradiation, in all cases varying
less than 6% between these two measurements after cleaning
the tip. All source and detector fibres were sterilised for
15 min in 0.85% sodium hydroxide solution and rinsed in
sterile saline immediately before use.
The light fluence (J cm-2) at the anticipated boundary of
necrosis was determined by integrating direct continuous
measurements of the local fluence-rate in the target volume
during PDT (Powers and Brown, 1986; Lilge and Wilson,
1993) using three implanted optical fibre probes. These
fluorescent (rhodamine 640) tipped probes (170 gm outer
Table I Summary of study groups
Intravenous
photosensitiser No. of animals Treatment Delivered
dose Tumour- time interval light energy
Group Photosensitiser mgkg-' bearing Normal (h) (J)
1 Photofrin 10 2 2 4-6 77-100
2 Photofrin 10 6 4 24 100
3 Photofrin 10 3 2 48 82-100
4 HpD 10 0 2 24 90-100
5 5-ALA 100 1 2 6 100
Control None - - 3 - 100Intracranial photodynamic therapy
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diameter) have been described elsewhere and were calibrated
for absolute fluence-rate response (Lilge et al., 1993b). They
were mounted in 26 G needles in a template along a line
parallel to and at the same depth as the treatment fibre, at
radial distances, r, of 2, 4 and 6 mm (Figure 1). This allowed
easy alignment to avoid severing of superficial blood vessels
of the cortex. The probe outputs were imaged onto a CCD
array (Photometrics, Tuscon, AZ, USA) for simultaneous
collection from the three positions in the tissue. A
semilogarithmic plot of the product of fluence times radial
distance vs radial distance from the source showed a linear
relationship, the negative slope of which yields the effective
attenuation coefficient, I1eff, of the tissue at the treatment
wavelength. [This relationship comes from the fact that the
fluence rate decreases with distance from the source
according to the combination of exponential attenuation
and a llr geometrical factor (Driver et al., 1991).] From this
plot, the fluence [H(rc)] at the radius of necrosis, rc, in each
animal was determined by interpolation.
Surgical preparation and light treatment were performed
under aseptic conditions. For light treatment the animals
were anaesthetised as described above. During surgery
inhalation of isoflurane (Forane; Anaquest, Mississauga,
Ontaria, Canada) at 2-3.5% (v/v) in either oxygen (100%)
or in an oxygen-nitrous oxide mixture (30-70%) was used
as required to maintain anaesthesia. The gas flow rate was
adjusted to 2.5 min-'. The oxygen saturation and partial
pressure in arterial blood (pao2) were measured in selected
rabbits breathing 100% oxygen before and after intracranial
light treatment. The oxygen saturation was found to be
99.8% at pao2 of 43.1-51.4 kPa before and after surgery
(Albritton, 1953). Surgery for intracranial light irradiation
required approximately 1.2-2 h. The skull was exposed and
a left parietal craniotomy of 12- 15 mm diameter performed.
The dura was incised and reflected. The source and detector
fibres were positioned under micrometer control to a depth
of 6 mm below the cortex surface via biopsy needles. The
needles were then retracted, leaving the optical fibres
embedded in the white matter, 3-5 mm from the left
hippocampus. In tumour-bearing animals the delivery fibre
was placed as close as possible to the initial tumour cell
injection site and depth, attempting to target the centre of
the tumour. The detector fibres were placed posteriorly or
posteromedially to the delivery fibre.
After irradiation the optical fibres were retracted and the
scalp was sutured. Recovery from anaesthesia was continu-
ously monitored. Dexamethasone 0.5 mg twice daily and
enrofloxacin (Baytril; Haver-Lockhart, Etobicoke, Ontario,
Canada) as antibiotic 12.5 mg daily were administered i.m.
The surface of the brain was exposed to a maximum
broad-band irradiance of 3.6 J cm-2 (approximately 7 J total
energy) from ambient operating room light. At 6 mm depth
the contribution of this to the treatment fluence was
negligible (<1%) and could not be detected by the
implanted detector probes.
The first five animals in the treatment groups were
irradiated with approximately 55 mW delivered power
(multiline mode) to minimise the exposure time. However,
occasional charring at the delivery fibre tip was observed, and
the output was reduced to 42-48 mW (single line) for all
subsequent treatments, with no further charring or damage to
the fibres. Delivery of 77-100 J total energy took up to
35 min.
Even although this extreme temperature effect at the fibre
tip had been eliminated, there remained the possibility that
the PDT treatment light could induce hyperthermia. Normal
brain tissue is highly temperature sensitive, and hyperther-
mia approximately 40-42°C has been shown to be
synergistic with PDT (Dereski et al., 1995a) and can lower
PDT threshold values (Farrell et al., 1991). Hence, in an
additional non-tumour-bearing rabbit in situ temperature
measurements were made in the brain by inserting three
calibrated type-T thermopiles via 25 G needles at 2, 4 and
6 mm from the source fibre at the same depth as the
detector fibre array in the treatment groups. All other
procedures were as for the PDT treatments, except that no
photosensitiser was given and no detector fibres were used.
Five minutes after inserting the temperature probes,
measurements were made for periods of 15 min at each of
35, 46, 52, 60 and 80 mW delivered power. At 80 mW the
maximum temperature increase, at the 2 mm position, was
1.5°C. At 60 mW and below, the maximum rise recorded
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Figure 1 Experimental set-up for intracranial PDT treatments and light fluence measurements. The delivery and detector fibres
were inserted under micrometer control to a depth of 6 mm below the brain surface, into either the white matter or the tumour
mass.was less than I°C at any time or position. Thus,
hyperthermia should not have been a significant factor in
the tissue response under the irradiation conditions used.
Determination of the radius of PDT-induced tissue necrosis
The animals were sacrificed 24-48 h post PDT treatment
(Yoshida et al., 1992b) by i.v. sodium pentobarbital overdose
(Euthanyl; Haver-Lockhart, Etobicoke, Ontario, Canada).
The brain was immediately removed intact and placed in
10% formalin in PBS. After fixation the brain was sliced into
transverse sections 3 mm thick for gross examination. Serial
-sections (4 ,um) were cut from those transverse slices that
showed the maximum area of necrosis. These were stained
with haematoxylin and eosin (H&E) to enhance coagulative
necrosis.
The area of induced necrosis, in a 2-D section, was
determined by video microscopy at 25 x magnification using
a colour CCD camera (Javelin, Japan) and a computer-based
image analysis program (Bioquant; R&M Biometrics,
Nashville, TN, USA). Necrosis was often delineated by the
lateral ventricle or a sulcus, causing non-spherical lesions.
The 'effective' radius of necrosis was calculated assuming a
spherical lesion with a maximum cross-sectional area equal to
the measured area.
In tumour-bearing animals, some necrosis of normal brain
from PDT was inevitable, and the area of necrosis comprised
both normal and tumour tissue. It has been reported (Dereski
et al., 1991; Yoshida et al., 1992b) that the area of neuronal
damage in normal brain usually extends beyond the area of
frank coagulative necrosis. This was, therefore, also scored in
each animal. The area of frank necrosis corresponds to
'intended' damage in tumour, while neuronal damage is the
concomitant extent of damage in adjacent normal brain.
Determination ofphotosensitiser concentration in tissue
For photosensitiser uptake studies one tumour-bearing
animal was sacrificed by i.v. euthanyl overdose at each light
treatment time point after photosensitiser injection. The brain
was immediately removed and stored at - 80°C until further
use. The right hemisphere was regarded as normal brain (N)
and the mid-section of the left hemisphere as tumour (T). The
anterior and posterior parts of the left hemisphere were
treated as brain adjacent to tumour (BAT). Aliquots of 100-
200 mg of each tissue were weighed and the porphyrins
extracted with ether (Mang et al., 1987). The porphyrin
concentration was then determined by optical absorption
spectroscopy at the Soret band (403 nm), to measure total
porphyrin content in the tissue, calibrated by spiking a
corresponding control homogenised tissue sample with a
known concentration of either Photofrin, HpD or PpIX free
acid, each dissolved in a 1:1 mixture of 0.01 N tetrahy-
drofuran and 0.1 N hydrochloric acid. Since this chemical
extraction does not differentiate between exogenous and
endogenous porphyrins, the concentration of the latter was
measured in tissues from an unsensitised rabbit and
subtracted from the uptake in the photosensitiser-injected
animals. The use of absorption spectroscopy for photo-
sensitiser quantification rather than fluorescence spectroscopy
Intracranial photodynamic therapy
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(Vernon et al., 1995) allows the total porphyrin content to be
determined, independent of differences in fluorescence yield
of the different porphyrin moieties in Photofrin and HpD. It
has the disadvantage of lower sensitivity than the fluorimetric
technique. The assumption that endogenous porphyrins do
not contribute significantly to the photodynamic effect is
supported by observations in the light-only control animals
(see below).
Determination of the photodynamic threshold value
The photodynamic threshold value, T (photons cm-3), was
calculated (Patterson et al., 1990) according to
T = 2.3ECH(r,)
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(1)
where e is the extinction coefficient (cm-' (jg g-')-') of the
photosensitiser at the treatment wavelength, C (,ug g-1) is the
tissue concentration of the photosensitiser and H(rc) (photons
cm-2) is the photon fluence at the radius of necrosis rc (mm).
By defining the photodynamic threshold in units of photons
cm-' it becomes independent of the treatment wavelength.
The extinction coefficients of the photosensitisers were
measured in dilute solutions (of dextran for Photofrin and
HpD, PBS for ALA) in a double-beam spectrophotometer in
the green-to-red part of the visible spectrum. The measured
values at the treatment wavelength of 514 nm compare well
with those in other studies (Profio and Doiron, 1981; Gunter
et al., 1989): Photofrin=0.011, HpD=0.038 and PpIX=
0.0002 cm-' (pg g-')-'. The photosensitiser concentrations in
tissue were determined as average values in each study group.
A quantum energy of 2.45 eV was used to convert J cm-'
into photons cm-' for the threshold calculation.
The photodynamic threshold was calculated for each
animal based on the individually measured radius of tissue
damage, the fluence at this radius and the group-average
values for the photosensitiser concentration. Values for rc and
T are presented as mean + SD within each study group.
Results
A total of 27 evaluable rabbits received intracranial PDT and
local fluence-rate measurements. One animal died of
unknown cause within 12 h of PDT treatment. In the three
control animals (light -no photosensitiser) only mechanical
damage from insertion of the fibre array was observed, with
no regional necrosis or zone of neuronal damage seen on
histopathology.
As seen in Table II, the tumour-to-normal brain ratio for
Photofrin uptake was approximately 12: 1 between 4 and
48 h. Highest porphyrin concentrations were found at short
time delays, probably due to circulating drug. The data also
suggest that uptake of HpD in normal brain is approximately
the same as for Photofrin, consistent with previous findings
(Wilson et al., 1988).
Different parts of the brain are involved in haem synthesis
(Verma et al., 1993), converting 5-ALA to PpIX. Regional
differences in synthesis of PpIX from 5-ALA in normal brain
have been observed (M Olivo, unpublished results). However,
Table II Photosensitiser uptake for the different study groups after subtracting the control values in each tissue; each data point represents a
single tissue sample
Injected dose Time interval Tumour Brain BAT
Group Photosensitiser (mgkg-') (h) (Pgg-') (ougg-') (gg '-1)
I Photofrin 10 4-6 13.0 1.0 1.2
2 Photofrin 10 24 8.1 0.7 2.2
3 Photofrin 10 48 7.0 0.5 2.1
4 HpD 10 24 NA 0.5 NA
5 5-ALA 100 6 10.3a 1.5a l.7a
Control None 0 - 0.1 <0.1b 0.1
a Concentration ofPpIX.
b Lower detection limit 0.1 ,pgg
NA, not available.M Intracranial photodynamic therapy
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the bulk sampling of tissue done here does not distinguish
specific areas involved in PpIX synthesis. Thus, the data in
Table II for PpIX are average tissue values. The PpIX
tumour-to-normal brain ratio was approximately 6: 1 at 6 h
after 5-ALA injection.
Figure 2 shows examples of the measured fluence rates,
¢D(r), as a function of time during light treatment. The
measured fluence rates changed by up to 50% during the
course of treatment in individual animals, but no systematic
pattern was observed in any of the study groups. As
discussed in the appendix, variations in the local fluence
rate, as for example in Figure 2c at 300 s, are most likely due
to changes in the local optical properties, rather than
fluctuations in delivered power, which would cause a
corresponding change in all detector readings. Based on the
measured fluence rates, @D(r), the total integrated fluence,
H(r), at each radial distance, H(r) from the source fibre was
calculated and plotted as r H(r) vs r for each animal, as
illustrated in Figure 3. The fluence (J cm-2) at the damage
Aw
radius could thereby be determined in each animal by linear
interpolation of these data, and was typically in the range
10 -14 J cm-2. The fluence rate vs distance measurements
also allowed the optical absorption and scattering coefficients
of the tissues to be determined, as discussed in the appendix.
Figure 4a shows a gross section of VX2 tumour. Histology
in tumour-bearing animals showed typical high-grade
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Figure 3 Example of a graph of the product (fluence x radius)
vs radius, measured by interstitial fluence-rate probes positioned
at radii of 2, 4 and 6mm from the source fibre tip. The fluences
were calculated from the measured fluence rates integrated over
the treatment time. The data points are for the same animals as in
Figure 2. *, Normal brain Photofrin at 48h; *, tumour, no
photosensitiser; A, tumour, Photofrin at 4h. The lines are linear
regression fits, the slopes of which yield the effective attenuation
coefficients, Peff, for each tissue. The white arrows indicate the
histologically determined radii of coagulative necrosis in the
tumour and normal brain of PDT-treated animals. The black
arrow indicates the radius of neuronal damage in normal brain.
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Figure 2 Local fluence rate at 2 mm (U), 4mm (0) and 6mm
(A) from the source fibre as a function of illumination time
during PDT treatment in three separate animals. (a) Normal
brain, Photofrin at 48 h. (b) Tumour, no photosensitiser. (c)
Tumour, Photofrin at 4h.
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Figure 4 Gross histology of VX2 tumour, showing (a) the
invasion into normal brain pretreatment and (b) the extent of
coagulative necrosis 24h after PDT with Photofrin at 24h.
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i .1 icarcinoma, growing along the major vessels, filling the
perivascular space and within the leptomeninges, and with
an oedematous BAT region. Figure 4b shows a gross
histological section of normal rabbit brain 24 h post PDT-
treatment. The PDT-induced lesions in normal brain were
characterised by areas of coagulative necrosis with a distinct
boundary (Figure 5a). This area of necrosis was bordered by
a rim of vacuoles, interpreted as a border of cerebral oedema.
This was followed by a thin rim of non-viable neurons, which
appeared shrunken and eosinophilic (Figure 6). The thickness
of this rim was generally 200-500 ,m, independent of the
photosensitiser type or time delay between its injection and
light irradiation.
a
b
c
Figure 5 H&E-stained micrographs of (a) normal brain 24h
after PDT with Photofrin at 24h, (b) VX2 tumour before
treatment and (c) VX2 tumour 24h after PDT with Photofrin at
24h. Necrosis in normal brain is surrounded by a rim of vacuoles
representing a border of cerebral oedema (a; large arrows) and
blood vessels showing fibrinoid necrosis (a; small arrows). The
VX2 tumour is seen growing along the vasculature (b; arrow).
Nests of viable tumour after PDT are visible within the necrotic
volume (c; arrows).
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In the tumour-bearing animals, nests and cords of viable
tumour were observed occasionally within brain tissue
adjacent to the PDT-induced necrotic lesions (Figure 5c).
Blood vessels within the lesions displayed fibrinoid necrosis in
both tumour and normal tissue. Occasional vessels displayed
features consistent with vasculitis: polymorphonuclear
leucocytes and mononuclear cells infiltrated throughout the
full thickness of vessel walls, and several vessels were
occluded by fibrin. Choroid plexus within and immediately
adjacent to the lesions frequently showed subepithelial
accumulations of fibrin and proteinaceous material. No
significant differences in the vascular effects were observed
for the different time delays between photosensitiser injection
and treatment.
No quantitative differences were found in either gross or
stained sections between HpD- and Photofrin-injected
animals. With 5-ALA, necrosis of normal brain could be
found only in the grey matter (Figure 7a), appearing similar
to Photofrin-induced coagulative necrosis in the grey matter.
No necrosis or subnecrotic effects were found in the white
matter.
The measured radii of tissue necrosis, rc, in the different
study groups are given in Table III. There was little
dependence of rc with time interval. No statistically
significant difference was observed between Photofrin and
HpD treated at 24 h. No statistically significant difference in
tissue response of animals receiving 100% oxygen or the
oxygen/nitrous oxide mixture was observed for normal or
tumour-bearing animals (data not shown).
As seen in Table III there was some inter-animal
variability in the radius of necrosis. Vascular damage and
shutdown contributes to PDT-induced coagulative necrosis
and can account for non-spherical lesions and significant
intra-animal variation in the extent of coagulative damage.
Patchy uptake of the photosensitiser (Boggan et al., 1984;
Hebeda et al., 1995), not observable in our volume-average
uptake measurements, could also contribute to non-spherical
lesions and irregular appearance of tissue necrosis.
Based on the total fluence at the radius of necrosis, the
concentration of the photosensitiser in the tissue and its
molar extinction coefficient, the photodynamic threshold
value was calculated for each animal according to equation
(1). The average values for each study group are listed in
Table IV. The photodynamic thresholds for Photofrin- and
HpD-treated animals at 24 h were similar.
As a result of the absence of PDT-damage in the white
matter of ALA-treated animals, the zone of necrosis was not
spherical with the fibre tip at the centre. The upper limit to
the threshold value given in Table IV was calculated using a
value for the radius of necrosis derived from rc2= A/4 i where
A is the maximum cross sectional area of necrosis. The lower
Figure 6 H&E-stained micrograph of PDT-induced necrosis in
normal brain 24h after treatment with Photofrin at 24h. Damage
to the pyramidal neurons in the hippocampal region (large arrow)
can be observed beyond the boundary of coagulative necrosis
(small arrow).Intracranial photodynamic therapy
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Figure 7 H&E-stained micrographs of PDT-induced necrosis in
normal brain 24h after treatment with 5-ALA at 6h. (a) Necrosis
in a grey matter region 5-6 mm from the fibre tip. (b) White
matter shows only necrosis related to mechanical damage caused
by fibre insertion (arrow).
Table III Radius of necrosis in each study group: group
average ± standard deviation
Treatment
time rc (mm)
Group Photosensitiser (h) VX2 tumourNormal brain
I Photofrin 4-6 4.3+0.6 4.3+0.7
2 Photofrin 24 3.6+0.5 3.8+0.4
3 Photofrin 48 4.0+0.6 5.1 +0.4
4 HpD 24 NA 4.6+0.1
5 5-ALAa 6 2.8 >2.5
a Only one data point available. NA, not available.
Table IV Photodynamic threshold values for coagulative necrosis
in normal brain and VX2 tumour: group average+standard
deviation.
Treatment X 1018 (photons cm-3)
time VX2 Normal
Group Photosensitiser (h) tumour brain
1 Photofrin 4-6 4.2+±18 2.8+1.5
2 Photofrin 24 24+7 2.2+1.1
3 Photofrin 48 26 ± 7 1.2+0.4
4 HpD 24 NA 2.5+1.6
5 5-ALAs 6 1.2 0.04-0.35b
aOnly one data point available. bGrey matter only. NA, not
available. See text for definitions of the ranges with 5-ALA.
limit was calculated assuming r, =6 mm, which is the distance
from the fibre tip to the dura. Studies to confirm these
threshold values are in progress using surface illumination of
the grey matter, which will allow accurate determination of
the true depth of necrosis.
Using neuronal damage rather than necrosis as the
biological end point results in lower threshold values:
(1.9+ 1.2, 1.8+0.8 and 1.1 0.5) x 10's photons cm-' at 4-
6, 24 and 48 h, respectively, for Photofrin; (2.1 + 1.2) x 1018
photons cm-' at 24 h for HpD.
For simplicity, the effect of photosensitiser photobleach-
ing during light irradiation has not been taken into account
in calculating the threshold values above. Extension of
equation (1) to include photobleaching has been discussed
previously (Wilson, 1992). An estimate of the effect can be
obtained by considering the fraction of photosensitiser
bleached at the radius of necrosis. For example, for
Photofrin, the fluence at the radius of necrosis is
approximately 10 J cm-2 in both tumour and normal tissue
(Figure 3), so that, for a photobleaching rate of
0.036 cm2 J-1 (Potter et al., 1987), the fractional reduction
is approximately 15%. Thus, in ignoring the photobleaching
effect, the threshold values would be overestimated by
approximately this amount.
Discussion and conclusions
The use of the VX2 tumour in rabbits is costly and labour
intensive, so that only a limited number of animals could be
studied. While, for example, rat models have the potential to
generate statistically significant data using a large number of
animals (Chen et al., 1992a,b; Dereski et al., 1991), the
rabbit model was chosen here since it provides a large
enough cranial cavity to grow tumours of a suitable size and
to generate measurable lesions by interstitial light delivery
without acute morbidity. Additionally, the low-density to
high-density lipoprotein ratio in New Zealand White rabbits
is similar to that in humans, thus presenting a better model
of photosensitiser pharmacokinetics (Chapman, 1986;
Barclay, 1972). The choice of the rabbit model restricts the
intracranial tumour type that can be used, and there is no
glioma model available as there is for the rat (Kaye et al.,
1985; Dereski et al., 1995b). Nevertheless, the uptake ratio
of photosensitiser in tumour and BAT vs surrounding
normal brain is similar to those reported for some rat
glioma models: e.g. the tumour-to-normal ratio of Photofrin
concentration at 48 h post injection was approximately 14 in
a 9L glioma grown in Fischer rats (Dereski et al., 1995b),
the same as for VX2 in the rabbit brain. The PDT
'curability' of the intracranial VX2 is likely to be different
from that of glioma. However, this and the small number of
animals used, does not affect the major conclusions of the
present study with respect to the PDT threshold and the
qualitative comparison between tumour and normal tissue
sensitivities. The known immunogenicity of the VX2 tumour
in rabbits (Zagzag et al., 1988) should also not alter the
threshold values significantly, since the PDT-induced
necrosis was measured at a short time interval post
treatment.
In these experiments, the doses of photosensitiser used in
the PDT-treated animals were high compared with clinical
doses, as reviewed by Kostron et al. (1990), although similar
to other preclinical studies (Dereski et al., 1995a,b; Kaye and
Morstyn, 1987). This kept the tissue concentration the same
as for the uptake measurements, for which high doses gave
improved accuracy. Thus, the tissue concentrations were
directly applicable in calculating the threshold values,
avoiding the need to assume linearity between administered
dose and tissue concentration. Also, since the intent was to
create sizeable zones of necrosis in order to measure the radii
and fluences accurately, the higher concentration kept the
treatment time to a minimum for fluence rates which did not
cause tissue heating.Photofrin PDT threshold
The Photofrin and HpD uptake measurements confirm earlier
findings (Wilson et al., 1988; Hill et al., 1990; Ying et al.,
1992) of a very low volume uptake in normal brain. [Note
that no steroids were administered before light activation, so
that modification of the BBB, which could alter porphyrin
uptake (Origitano et al., 1993), need not be considered.] It is
generally believed that the intact BBB reduces diffusion of
Photofrin or HpD from the vasculature to the extravascular
space. The highest concentrations of Photofrin in normal
brain were found at short time intervals (4-6 h), possibly
due to circulating drug (Peng et al., 1991). The tissue
concentration decreased at longer times, although about
50% of the peak concentration still remained at 48 h. In a
mouse model the half-time for Photofrin clearance in plasma
was reported to be approximately 5 h (Peng et al., 1991), so
that the contribution of circulating drug at 48 h can be
neglected, and the concentration must be attributed to tissue-
associated photosensitiser. Very slow clearance of Photofrin
and HpD from normal human brain has also been reported
in other studies (Boisvert et al., 1985; Kaye et al., 1985).
The time course of Photofrin concentration in the tumour
was similar to that in normal brain, but with the peak uptake
being about 12 times higher, attributable to breakdown of the
BBB. Ying et al. (1992) noted in a rat glioma model that the
uptake of photosensitiser into malignant tissue increases with
progressive degradation of the BBB. As most human brain
tumours are currently treated at a late stage, it can be
assumed that the BBB is also disrupted, and similarly high
uptake can be expected (Origitano et al., 1993). Some
investigators (Pottier and Kennedy, 1990; Woodburn et al.,
1992) have pointed out that, in poorly vascularised tumours,
including human glioma (Kayama et al., 1991), the tissue is
more acidic, possibly increasing the uptake or retention of
photosensitisers such as HpD and Photofrin.
Despite the very low volume uptake of Photofrin and
HpD in normal brain, significant necrosis was produced at all
times, resulting in a very low photodynamic threshold value
compared with other normal tissues (Patterson et al., 1990)
(see Table V). The most likely explanation is that the intact
BBB results in a very high concentration of photosensitiser in
the capillary endothelium, and necrosis results from
microvascular damage (Reed et al., 1987). Our finding of
subepithelial accumulations of fibrin and proteinaceous
material adjacent to the PDT lesions suggest a subnecrotic
effect of PDT on the vasculature.
The decrease of the photosensitiser concentration in
normal brain and tumour at longer time intervals is not
reflected in a decrease of the radii of necrosis. Thus, the
threshold values decrease with time. This can only be
explained by either a redistribution of photosensitiser to
more sensitive target sites or selective removal of photo-
sensitiser from less sensitive sites. Berenbaum et al. (1986)
Intracranial photodynamic therapy
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reported high sensitivity of normal rat brain to Photofrin
PDT up to 84 days after injection and M Dereski (personal
communication) found no change in the radius of Photofrin
PTD-induced necrosis in normal rat brain several weeks after
photosensitiser administration. Chen et al. (1992a,b) derived
very low photodynamic threshold with Photofrin for
transdural illumination of the grey matter in rats, suggesting
different PDT sensitivity for white vs grey matter.
The relatively high Photofrin PDT threshold value in the
well-vascularised intracranial VX2 tumour is similar to that
in the poorly vascularised and poorly differentiated Dunning
prostate tumour grown subcutaneously (M Olivo, unpub-
lished results), and may be due to rate-limiting perfusion of
oxygen in the intracranial tumour as the result of competitive
oxygen use in adjacent brain tissue. This has been suggested
by Lindsay et al. (1991), who observed reduced PDT
response of malignant glioma in rats grown intracranially
compared with extracranially. Comparative studies of the
PDT threshold in the VX2 tumour under these conditions are
in progress. Kayama et al. (1991) found that the intra-
tumoral P02 was four times lower than in the brain cortex
and up to eight times lower than in arterial blood, measured
during surgery in humans. The arterial pao2 measured in our
experiments during PDT was close to four times lower than
reported in the human study. Hence, very poorly oxygenated
regions could be present in the VX2 tumour despite a good
vascular supply, resulting in reduced sensitivity to photo-
dynamic therapy (Foster et al., 1991).
Photofrin PDT vs HpD PDT threshold
Kaye and Morstyn (1987) have reported smaller depths of
necrosis of normal rat brain vs a glioma tumour model,
treated using HpD under similar conditions, suggesting a
higher threshold for necrosis in normal brain when using
HpD compared with Photofrin. However, we observed no
significant differences in the radius of necrosis in normal
rabbit brain treated with either HpD or Photofrin. Parallel
studies in a 9L glioma rat model (Q Chen and M Dereski,
private communication) have found also no difference in the
response of normal brain tissue to HpD and Photofrin. In the
use of PDT for human patients, there appears to be a greater
degree of normal brain response with Photofrin (Muller and
Wilson, 1993) than with HpD (Kaye and Hill, 1993), as
observed clinically. With Photofrin, elevated intracranial
pressure, approximately double those of a resection-only
control group, requiring high doses of steroids, have been
reported (Muller and Wilson, 1993), suggesting significant
cerebral oedema. This has not been reported to be a problem
with HpD. Conversely, in neither case does there appear to
be neurological deficit as result of the treatment, which is
consistent with our finding that Photofrin and HpD have
similar PDT effects on normal brain.
Table V Summary of photodynamic threshold values for comparison with Table IV
Time T
interval X 1018
Tissue Photosensitiser (h) (photons cm-3) Reference
Liver (rat) AISPc 24 38 Patterson et al. (1990)
Photofrin 24 3.5 Farrell, (1991)
Human tumour Photofrin 24 1.5a Derived from
(Head and neck) Wenig et al. (1992)
Human tumour Photofrin <72 0.863 Derived from
(various) Potter, (1989)
Dunning prostate AISPc 24 20 M Olivo (unpublished
Tumour (rat flank) results)
Rat brain Photofrin 24 1.5bc Ying et al. (1994)
Rat brain Photofrin 48 <1cd Chen et al. (1992a) and
Dereski et al. (1991)
a Applying assumed values for photosensitiser uptake and light penetration. b Assuming a photosensitiser concentration of 0.5 ,ugg-1 tissue for
12.5mgkg--' injected dose. c Necrosis limited mostly to grey matter. d Assuming a photosensitiser concentration of 0.2 ugg-1 for 4mg kg-' injected
dose (based on the same specific uptake as Dereski et al., (1991). AISPc, Aluminium chlorosulphonated phthalocyanine (tetrasulphonated).Intracranial photodynamic therapy
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5-ALA PDT threshold
In vivo synthesis of the photosensitiser PpIX from adminis-
tration of 5-ALA is part of the haem synthesis pathway.
Verma et al. (1993) showed that haem synthesis in normal rat
brain is mainly restricted to the grey matter and olfactory
bulb, possibly with the highest activity in the cortex. While
Percy and Shanley (1977) showed that 5-ALA uptake in
human cerebrospinal fluid is low for moderate blood serum
concentrations (approximately 1 mg I') during acute por-
phyria, McGillion et al. (1974) showed that 5-ALA can cross
the BBB and accumulate in the cerebrospinal fluid of rats at
elevated plasma concentration (20 mg 11). In this study,
administering 5-ALA at 100 mg per kg bw i.v., we found a
higher concentration of PpIX in tumour and a lower tumour-
to-normal brain ratio than reported by Fukuda et al. (1992)
after injecting liposomally encapsulated 5-ALA at 200 mg per
kg bw i.v. into mice. This suggests that the low molecular
weight 'free' 5-ALA can cross the intact BBB and is taken up
by both normal and tumour tissues more efficiently than
encapsulated 5-ALA. As white matter does not synthesise
PpIX in high amounts, PDT treatment of deep-seated
tumours in the white matter could be possible with a high
therapeutic selectivity. This is also suggested by the lower
tumour-to-normal threshold ratios for 5-ALA compared with
the other photosensitisers. The extremely low threshold for
regions of normal brain active in haem synthesis, including
the grey matter, would require very careful application of
PDT irradiation to spare these regions.
In conclusion, the photodynamic threshold model appears
to be applicable to quantify the extent of PDT-induced
tissue necrosis in intracranial tissues with the photosensitiser
and irradiation parameters used here. The study has
confirmed the high intrinsic PDT-sensitivity of normal
brain. This is of concern when applying PDT as clinical
treatment for human brain tumours. In order to achieve a
good therapeutic effect with a wide margin of safety, the
tumour-to-normal photodynamic threshold ratio should
ideally be much less than unity. Since this is not the case,
selective tumour destruction can only be achieved by having
a high tumour-to-normal uptake ratio of photosensitiser and
by accurate light targeting. Increase in the therapeutic ratio
using alternative photosensitisers and/or modulating the
PDT effect in normal brain is a worthwhile goal. Assuming
that damage to normal brain is caused by vascular stasis,
triggered by damage to the endothelium, protection might be
achieved by clearance of the photosensitiser from the BBB
before light treatment or bleaching of the photosensitiser at
the onset of light treatment (Patterson and Wilson, 1994) to
prevent endothelial cell damage, or suppression of clotting
factor release after the endothelial cell layer is damaged (Ben
Hur et al., 1988), or by administration of thromboxane
inhibitors to prevent vascular stasis (Fingar et al., 1993).
Detailed subcellular photosensitiser uptake studies, for
example using confocal fluorescence microscopy (M Olivo,
unpublished results), can play an important role in
evaluating the possible efficacy of some of these interven-
tions.
The observation of neuronal damage beyond the zone of
coagulative damage in normal brain with Photofrin or HpD
may also reduce the therapeutic efficacy of brain tumour
PDT. The extent of neuron damage beyond coagulative
Appendix
The fluence at the boundary of necrosis can be calculated indirectly
by applying a mathematical model of the light distribution in
optically turbid media (Driver et al., 1991; Arnfield et al., 1992;
Farrell and Patterson, 1992) based on average optical properties of
the target tissue. In the present study, in addition to direct
determination of the fluence at the radius of necrosis, the local
fluence-rate measurements, ¢(r), at the three different radial
distances, r, were used to derive the optical interaction coefficients
of the target tissues, using a modified solution of the diffusion
necrosis becomes smaller for longer time delays between
photosensitiser and light administration, favouring longer
time delays (Muller and Wilson, 1993).
For Photofrin the maximum normal-to-tumour threshold
ratio was obtained at 24 h. Of the five study groups, 5-ALA
had the highest normal-to-tumour threshold ratio in white
matter, and could be a very efficient photosensitiser for
tumours seeded in this location. However, care will have to
be taken to protect haem-synthesising structures in the brain
from light irradiation, considering also that photoproducts are
created when PpIX is light activated (Charlesworth and Trus-
cott, 1993) and these could have different photoeffectiveness.
The large variation observed during light treatment in the
local fluence rate and, hence, in the tissue optical properties
emphasises the need for continuous fluence-rate monitoring
during clinical PDT. The multifibre detector technique
demonstrated might be well suited for deep-seated malig-
nancies when non-invasive monitoring (Farrell et al., 1992b;
Farrell and Patterson, 1992) is not applicable.
Finally, the possible relevance ofthe present work to clinical
PDT for treatment of malignant brain tumours should be
considered. The low occurrence ofreportedmajorneurological
deficits with Photofrin or HpD PDT in patients, (Muller and
Wilson, 1993; Kaye and Hill, 1993) might be interpreted as
challenging the present conclusion that normal brain has an
intrinsically higher sensitivity to porphyrin-based PDT than
brain tumour. However, it should be noted that the fraction of
normal brain exposed during PDT in patients has generally
been much less than in this rabbit model, even allowing for the
fact that the clinical studies have been carried outusing 630 nm
light, where the penetration in tissue is much greater than at
514 nm. Thus, either there could be damage to normal human
brain that is subclinical, or normal human brain does not have
high sensitivity compared with brain tumour, or the high
sensitivity in the normal rabbit brain is (partially) the result of
the large fractional volume exposed or the relatively high
photosensitiser doses used. Further studies to examine the last
point are in progress. In the absence ofevidence to the contrary,
it also seems reasonable to proceed with further studies using
the present model to examine possible alternative photosensi-
tisers that may have significantly less effect on normal brain
tissue and strategies to enhance the PDT sensitivity of
intracranial tumour relative to surrounding normal brain.
This is likely to be increasingly important as PDT is used to
eradicate minimal residual tumour after surgical resection or
small tumour foci without prior resection, when tumour
selectivity will be critical.
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equation (Grosjean, 1956). This solution of the diffusion equation has
been confirmed by Monte Carlo calculations close to the source and
is equally accurate for scattering- or absorption-dominated tissues
(Arnfield et al., 1992). The reduced (transport) scattering coefficient,
u,', and absorption coefficient, Ma, were derived as free parameters in
a gridsearch X-square fit to the measured 4>(r) values and the mean
delivered power before and after treatment. A geometrical correction
for anisotropic delivery by the cut-end optical fibre was incorporated
in the mathematical model (Lilge & Wilson, 1993). The effectiveIntracranial photodynamic therapy
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Figure AlI Reduced scattering coefficient ()and absorption
coefficient (U) of tissues as a function of treatment time, derived
from the local interstitial fluence-rate measurements shown in
Figure 2. (a) Normal brain, Photofrin at 48 h. (b) Tumour, no
photosensitiser. (c) Tumour, Photofrin at 4 h.
attenuation coefficient, yfYi, which determines the exponential
component of the fluence profile, was calculated from the absorption
and scattering coefficients, using diffusion theory (Patterson et al.,
1991).
The resulting optical properties of normal rabbit brain and VX2
tumour are given in Figure Al for each data set shown in Figure 2.
Table Al Optical properties of normal rabbit brain and VX2
tumour at 514nm, pre-PDT group average±standard deviation.
Indirecta Directb
Pa [Us Pe.f- elf
n (mm-') (mm-l) (mm ') (mm-l)
VX2 tumour 12 0.092+0.03 2.0+ 1.1 0.7+0.2 0.7+0.1
Normal brain 12 0.11+0.06 2.2+ 1.3 0.9+0.2 0.8+0.3
a From [Ia and ,i' values, determined from fitting the local fluence-
rate to diffusion theory.
b Determined from the slope ofln[r D(r)] at onset of PDT.
Variations in the local fluence-rate, as seen in Figure 2, are here
reflected in these optical properties changing during the course of the
treatment, Note that the sudden discontinuity seen in Figure 2 is not
reflected in the derived optical properties values. The average values
of /la, p,' and p,ff during light treatment are shown in Table Al. The
effective attenuation coefficients alternatively derived directly from
the semilogarithmic plots of r H(r) vs r, as shown in Figure 3, are
also included in Table Al. The difference between the directly and
indirectly determined values was generally less than 15%, in support
of the mathematical model used to derive the absorption and
scattering coefficients. In some animals the linear regression to
calculate jp,,1 directly and the fitting routine to derive JUa and i,'
showed significant errors, possibly due to individual detector fibres
being close to strongly light-absorbing structures (e.g. blood vessels
or blood clot). The precision of these interstitial fluence-rate
measurements could be increased either by increasing the number
of optical fibre detectors (Lilge and Wilson, 1993) or by a different
geometrical arrangement of these around the source fibre.
The average optical properties and penetration depth (1/y,es) of the
514 nm light in normal brain are similar to published values (Svaasand
and Ellingsen, 1983; Chen et al., 1992b). Literature data for brain
tumour are only available for 630 nm light, for which the penetration
depth is substantially greater, 2.9+ 1.5 mm (Muller and Wilson, 1986),
than at 514 nm, due mainly to reduced haemoglobin absorption.
Monitoring of the fluence-rate during light treatment was found
to be essential, as the fluence-rate distribution in brain tissue could
alter unpredictably in the course of treatment, as seen in Figure 2 at
particular times and locations. This type of sudden change in fluence
rate was seen sporadically in a number of animals during treatment.
It is not likely to be a technical artifact, such as movement of the
fibre tip or changes in the fibre-detector coupling, since the change
was usually transient and reversible. It is also not the result of a
sudden loss or gain in delivered light, since this would be seen by all
detectors equally. The most probable cause is local tissue disruption
in the region of the individual detector fibre tip, such as an altered
blood content in a nearby vessel or some bleeding around the
detector, although the latter would not be rapidly reversible. The
haemoglobin extinction coefficient is very high at 514 nm as used
here, so that relatively small changes in local blood content could
give marked fluence changes. We have also seen these effects in other
tissues, such as the canine prostate (Q Chen, unpublished results).
Considering the slower, systematic trends in optical properties
during treatment, reduced optical absorption due to photosensitiser
photobleaching (Wilson et al., 1986) can be neglected in normal brain
owing to the minimal contribution of the photosensitiser to the
overall absorption coefficient (estimated at 0.0038 cm-' vs
0.11 cm-'). However, it has to be considered for Photofrin and
HpD in tumour tissue, as up to 15% of the overall absorption can be
due to the photosensitiser. Changes in the scattering coefficient could
be caused, for example, by oedema or fluid (e.g. cerebrospinal fluid)
leaking into the target volume, or by incidental thermal damage to
the tissue (King and Rudolf, 1993; Jaywant et al., 1993), although the
latter is unlikely for the temperature changes observed. Direct
monitoring of the fluence rate would enable compensation in clinical
treatment time for such changes in the tissue optical properties due to
the treatment itself.
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